David A. Siegel Erasca, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Erasca, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 843,300 shares of ERAS stock, worth $2.26 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
843,300
Previous 1,035,900
18.59%
Holding current value
$2.26 Million
Previous $2.13 Million
6.7%
% of portfolio
0.0%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding ERAS
# of Institutions
133Shares Held
205MCall Options Held
3.1KPut Options Held
142K-
Vr Adviser, LLC New York, NY16.2MShares$43.5 Million4.2% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA16.2MShares$43.5 Million2.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$36.9 Million1.36% of portfolio
-
Arch Venture Management, LLC Chicago, IL11.1MShares$29.6 Million15.29% of portfolio
-
Black Rock Inc. New York, NY10.6MShares$28.4 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $327M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...